1-4 of 4
Keywords: Des-γ-carboxy prothrombin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma

Subject Area:
Oncology
Teiji Kuzuya, Naoto Kawabe, Senju Hashimoto, Ryoji Miyahara, Akira Sawaki, Takuji Nakano, Kazunori Nakaoka, Hiroyuki Tanaka, Yohei Miyachi, Arisa Mii, Sayaka Kamejima, Takeshi Takahara, Yutaro Kato, Atsushi Sugioka, Yoshiki Hirooka
Journal: Oncology
Oncology (2022) 100 (1): 12–21.
https://doi.org/10.1159/000519448
Published Online: 03 November 2021
... changes in alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) levels in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab and to evaluate the relationship between changes in these tumor markers and treatment efficacy. Methods: Of 58 consecutive...
View article titled, Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma
Open the PDF for Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma in another window
Journal Articles

Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization

Subject Area:
Oncology
Takeshi Ichikawa, Nobuaki Machida, Hiroshi Sasaki, Akira Tenmoku, Hiroaki Kaneko, Ryoju Negishi, Itaru Oi, Masayuki A. Fujino
Journal: Oncology
Oncology (2016) 91 (6): 317–330.
https://doi.org/10.1159/000448999
Published Online: 27 October 2016
... patients with unresectable HCC treated with initial TACE. α-Fetoprotein (AFP) or des-γ-carboxy prothrombin (DCP) response was assessed in patients who had baseline AFP levels ≥200 ng/ml or DCP ≥60 mAU/ml; a positive response was defined as a reduction of >50% compared to baseline 1 month after TACE...
View article titled, Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization
Open the PDF for Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization in another window
Journal Articles

Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma

Subject Area:
Oncology
Teiji Kuzuya, Yasuhiro Asahina, Kaoru Tsuchiya, Keisuke Tanaka, Yuichiro Suzuki, Takahide Hoshioka, Shinji Tamaki, Tomoji Kato, Yutaka Yasui, Takahiro Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Namiki Izumi
Journal: Oncology
Oncology (2011) 81 (3-4): 251–258.
https://doi.org/10.1159/000334454
Published Online: 23 November 2011
... was to investigate the relationships between early changes in the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), and antitumor response in the early period following administration of sorafenib in patients with advanced hepatocellular carcinoma (HCC). Methods: Forty-eight advanced HCC...
View article titled, Early Decrease in α-Fetoprotein, but Not <span class="search-highlight">Des</span>-<span class="search-highlight">γ</span>-<span class="search-highlight">Carboxy</span> <span class="search-highlight">Prothrombin</span>, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
Open the PDF for Early Decrease in α-Fetoprotein, but Not <span class="search-highlight">Des</span>-<span class="search-highlight">γ</span>-<span class="search-highlight">Carboxy</span> <span class="search-highlight">Prothrombin</span>, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma in another window
Journal Articles

Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: A Comparison of the Biomarker-Combined Japan Integrated Staging Score, the Conventional Japan Integrated Staging Score and the BALAD Score

Subject Area:
Oncology
Satoshi Kitai, Masatoshi Kudo, Yasunori Minami, Seiji Haji, Yukio Osaki, Hiroko Oka, Toshihito Seki, Hiroshi Kasugai, Yo Sasaki, Takashi Matsunaga
Journal: Oncology
Oncology (2008) 75 (Suppl. 1): 83–90.
https://doi.org/10.1159/000173428
Published Online: 17 December 2008
... (HCC). Recently, two new staging systems, the biomarker-combined JIS (bm-JIS) score and the BALAD score, have been proposed. Both staging systems include three tumor markers: α-fetoprotein (AFP), lens culinaris agglutinin-reactive AFP and des-γ-carboxy prothrombin specific for HCC. The aim...
View article titled, Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: A Comparison of the Biomarker-Combined Japan Integrated Staging Score, the Conventional Japan Integrated Staging Score and the BALAD Score
Open the PDF for Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: A Comparison of the Biomarker-Combined Japan Integrated Staging Score, the Conventional Japan Integrated Staging Score and the BALAD Score in another window